Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical and Experimental Immunology

• Publication date

  2000-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2249.2000.01119.xPMID 10606987PMCID PMC1905549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.

  1998cited by this paper
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• T‐cell‐mediated cytotoxicity against keratinocytes in sulfamethoxazol‐induced skin reaction

  1998cited by this paper
• Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma.

  1998cited by this paper
• Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses.

  1998cited by this paper
• Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma

  1998cited by this paper
• The anatomical basis of intestinal immunity

  1997cited by this paper
• Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.

  1997cited by this paper
• Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

  1996cited by this paper
• Lymphocytes subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood.

  1996cited by this paper
• Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine.

  1995cited by this paper
• Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells

  1995cited by this paper
• NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules

  1994cited by this paper
• BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity.

  1994cited by this paper
• Functional evidence that the HECA-452 antigen is involved in the adhesion of human neutrophils and lymphocytes to tumour necrosis factor-alpha-stimulated endothelial cells.

  1994cited by this paper
• Severe adverse cutaneous reactions to drugs.

  1994cited by this paper
• Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis.

  1994cited by this paper
• Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.

  1993cited by this paper
• Selective generation of CD8+ T‐cell clones from the peripheral blood of patients with cutaneous reactions to beta‐lactam antibiotics

  1993cited by this paper
• Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases.

  1992cited by this paper
• T-cell subsets in drug-induced toxic epidermal necrolysis.

  1992cited by this paper
• T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells.

  1991cited by this paper
• Human T cell clones use a CD3-associated surface antigen recognition structure to exhibit both NK-like and allogeneic cytotoxic reactivity.

  1987cited by this paper

• Case Report: A case of toxic epidermal necrolysis induced by serplulimab: integrated Chinese and Western nursing care.

  2026cites this paper
• Toxic epidermal necrolysis treated with plasma exchange in three patients receiving maintenance hemodialysis

  2025cites this paper
• Design of Therapeutic Vaccines Based on Antigen Epitopes of α-9 HPV E6 in Sichuan.

  2025cites this paper
• TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity

  2025cites this paper
• A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis

  2025cites this paper
• Fluconazole-induced Stevens-Johnson syndrome at Libreville University Hospital - Gabon: A case report

  2025cites this paper
• To Debride or Not to Debride: A Review of Wound Management for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2024cites this paper
• Effect of Early Cyclosporine Treatment on Survival in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2024cites this paper
• Spatial proteomics identifies JAKi as treatment for a lethal skin disease

  2024cites this paper
• Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis

  2024cites this paper
• Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

  2024cites this paper
• Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review

  2024cites this paper
• Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets

  2024cites this paper
• Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson Syndrome and Toxic epidermal necrolysis

  2024cites this paper
• Benefits of the use of porcine skin for the management of toxic epidermal necrolysis injuries: Review of the literature

  2024cites this paper
• D-Penicillamine-Induced Stevens–Johnson Syndrome in a Patient with Gold Cyanide Intoxication: A Case Report

  2024cites this paper
• Clinical Features of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor versus Non-Immune Checkpoint Inhibitor Drugs in China: A Cross-Sectional Study and Literature Review

  2024cites this paper
• Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy.

  2024cites this paper
• How to manage drug-virus interplay underlying skin eruptions in children

  2024cites this paper
• Single-cell spatial proteomics identifies the JAK/STAT pathway as an actionable therapeutic target in lethal cutaneous drug reactions

  2023cites this paper
• Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome

  2022cites this paper
• Viral infections and drug hypersensitivity

  2022cites this paper
• Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance

  2022cites this paper
• Immunohistological analysis of pathogenic infiltrates in the epidermis and liver of a patient with toxic epidermal necrolysis accompanied by vanishing bile duct syndrome

  2022cites this paper
• Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: Case report and literature review

  2022cites this paper
• IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin

  2022cites this paper
• A case of apalutamide‒induced toxic epidermal necrolysis that was treated with plasma exchange

  2022cites this paper
• Lethal allopurinol induced Lyell Syndrome

  2022cites this paper
• Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome

  2022cites this paper
• Small Molecule/HLA Complexes Alter the Cellular Proteomic Content

  2021cites this paper
• Understanding Immune Responses to Surgical Transplant Procedures in Stevens Johnsons Syndrome Patients

  2021cites this paper
• Lamotrigine and Stevens-Johnson Syndrome Prevention.

  2021cites this paper
• Current Perspectives on Severe Drug Eruption

  2021cites this paper
• Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis

  2020cites this paper
• Stevens-Johnson Syndrome and Its Manifestation in Oral Cavity

  2020cites this paper
• Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)

  2020cites this paper
• [Advances in understanding of the pathophysiology of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)].

  2020cites this paper
• Re-epithelialization and immune cell behaviour in an ex vivo human skin model

  2020cites this paper
• T-cell activation by low molecular weight drugs and factors that influence susceptibility to drug hypersensitivity.

  2020cites this paper
• Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

  2019cites this paper
• Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

  2019cites this paper
• Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China

  2019cites this paper
• Diverse expression of TNF-α and CCL27 in serum and blister of Stevens–Johnson syndrome/toxic epidermal necrolysis

  2018cites this paper
• Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2018cites this paper
• Immune Mechanisms of Drug Allergy

  2018cites this paper
• ALLOPURINOL INDUCED TOXIC EPIDERMAL NECROLYSIS: A CASE REPORT

  2018cites this paper
• HLAs: Key regulators of T‐cell‐mediated drug hypersensitivity

  2018cites this paper
• Approach to Severe Cutaneous Adverse Drug Reactions

  2017cites this paper
• Variable levels of apoptotic signal‐associated cytokines in the disease course of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis

  2017cites this paper
• New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.

  2017cites this paper
• Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.

  2017cites this paper
• Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

  2017cites this paper
• T Cell Immune Responses in Skin

  2017cites this paper
• Nécrolyse épidermique toxique : physiopathologie et avancées thérapeutiques

  2017cites this paper
• Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease.

  2016cites this paper
• Current perspective on the role of TNFα inhibitors in treating patients with toxic epidermal necrolysis

  2016cites this paper
• Pathway analysis for identification of potential biomarkers in severe cutaneous drug hypersensitivity reactions

  2016cites this paper
• A Review of the Pathogenesis of Toxic Epidermal Necrolysis.

  2016cites this paper
• Review of Toxic Epidermal Necrolysis

  2016cites this paper
• Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database

  2016cites this paper
• Immunologic Mediators in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

  2016cites this paper
• Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review.

  2015cites this paper
• Antiepileptic drugs and adverse skin reactions: An update

  2015cites this paper
• Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013.

  2015cites this paper
• HLA and the Pharmacogenomics of Drug Hypersensitivity

  2014cites this paper
• The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions

  2014influential citation
• Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology.

  2014cites this paper
• Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review.

  2014cites this paper
• SJS/TEN Overlap Associated with Lomefloxacin: Case Report and Molecular Typing Studies

  2014cites this paper
• Steven Johnson syndrome and toxic epidermal necrolysis: A review

  2014cites this paper
• A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with intravenous immunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels.

  2013cites this paper
• Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis): Historical considerations

  2013cites this paper
• In vitro drug causality assessment in Stevens–Johnson syndrome – alternatives for lymphocyte transformation test

  2013cites this paper
• immunoglobulin-like receptor killer cell - CD4+ cutaneous T-cell lymphoma cells express the p140

  2013cites this paper
• Toxic epidermal necrolysis: the year in review

  2013cites this paper
• Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis): Historical considerations

  2013cites this paper
• Now patients can spend less time thinking about their scars and more time seeing results

  2012cites this paper
• Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex.

  2012cites this paper
• A recent update of pharmacogenomics in drug-induced severe skin reactions.

  2012cites this paper
• Stevens-Johnson syndrome and toxic epidermal necrolysis.

  2012cites this paper
• Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens–Johnson syndrome and toxic epidermal necrolysis

  2012cites this paper
• Proteomic kinetic analysis of blister fluid and serum in a patient with drug-induced toxic epidermal necrolysis. A comparison with skin immunohistochemistry.

  2012cites this paper
• Immunological mechanisms of epidermal damage in toxic epidermal necrolysis

  2012cites this paper
• Drug-induced epidermal necrolysis: Important new piece to end the puzzle.

  2011cites this paper
• Cyclosporine for SJS/TEN: a case series and review of the literature.

  2011cites this paper
• In vitro diagnosis of T cell‐mediated drug allergy

  2011cites this paper
• A study of HLA class I and class II 4‐digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis

  2011cites this paper
• Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis

  2011cites this paper
• Expression of α‐defensin 1–3 in T cells from severe cutaneous drug‐induced hypersensitivity reactions

  2011cites this paper
• Autoimmunity at the ocular surface: pathogenesis and regulation

  2010cites this paper
• Toxic epidermal necrolysis (Lyell's disease).

  2010cites this paper
• New Insights in Toxic Epidermal Necrolysis (Lyell’s Syndrome)

  2010cites this paper
• Toxic epidermal necrolysis and Stevens-Johnson syndrome

  2010cites this paper
• CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

  2010cites this paper
• Personalized medicine for HLA-associated drug-hypersensitivity reactions.

  2010cites this paper
• In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug‐induced skin diseases

  2010cites this paper
• Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.

  2010cites this paper
• Functionally Active Macrophage-Derived Myeloperoxidase in the Skin of Drug-Induced Toxic Epidermal Necrolysis

  2010cites this paper
• Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis

  2010cites this paper
• 76. Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

  2010cites this paper